drugset

drugset / Trial / NCT01142089

Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)

NCT01142089 ↗

Phase 3 Completed 264 enrolled Cosmo Technologies Ltd Bausch Health Americas, Inc. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether Rifamycin SV MMX is a safe and effective treatment for Traveler's Diarrhea.

Timeline

Start: 2010-05-27
Primary completion: 2012-06
Completion: 2012-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rifamycin SV MMX	Unknown	400 mg	Oral

Indications